Blockade of Myeloid Suppressor Cells Overcomes the Anti-PD-1/PD-L1 Resistance in KRAS-Driven and LKB1-Deficient NSCLC

被引：0
|
作者：
Li, R. [1 ]
Salehi-Rad, R. [1 ]
Momcilovic, M. [1 ]
Lim, R. [1 ]
Ong, S. [1 ]
Huang, Z. [1 ]
Tran, L. [1 ]
Zhe, J. [1 ]
Paul, M. [1 ]
Teitell, M. [1 ]
Minna, J. [2 ]
Krysan, K. [1 ]
Shackelford, D. [1 ]
Liu, B. [1 ]
Dubinett, S. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] UTSW, Dallas, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A11
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [1] Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Salvia, Roser
    Rico, Laura G.
    Moran, Teresa
    Bradford, Jolene A.
    Ward, Michael D.
    Drozdowskyj, Ana
    Climent-Marti, Joan
    Martinez-Caceres, Eva M.
    Rosell, Rafael
    Petriz, Jordi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [2] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Niu, Mengke
    Yi, Ming
    Li, Ning
    Luo, Suxia
    Wu, Kongming
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [3] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Mengke Niu
    Ming Yi
    Ning Li
    Suxia Luo
    Kongming Wu
    Experimental Hematology & Oncology, 10
  • [4] Depletion of CXCR2-dependent myeloid-derived suppressor cells (MDSCs) overcomes anti-PD-1 resistance in a murine model of LKB1-deficient non-small cell lung cancer (NSCLC) with high mutational load
    Li, Rui
    Salehi-Rad, Ramin
    Ong, Stephanie
    Momcilovic, Milica
    Liu, Bin
    Lim, Raymond
    Linh Tran
    Huang, Ziling
    Jing, Zhe
    Paul, Manash
    Krysan, Kostyantyn
    Park, Stacy
    Minna, John
    Teitell, Michael
    Shackelford, David
    Dubinett, Steven
    CANCER RESEARCH, 2019, 79 (13)
  • [5] TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
    Bertrand, Florie
    Montfort, Anne
    Marcheteau, Elie
    Imbert, Caroline
    Gilhodes, Julia
    Filleron, Thomas
    Rochaix, Philippe
    Andrieu-Abadie, Nathalie
    Levade, Thierry
    Meyer, Nicolas
    Colacios, Celine
    Segui, Bruno
    NATURE COMMUNICATIONS, 2017, 8
  • [6] TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
    Florie Bertrand
    Anne Montfort
    Elie Marcheteau
    Caroline Imbert
    Julia Gilhodes
    Thomas Filleron
    Philippe Rochaix
    Nathalie Andrieu-Abadie
    Thierry Levade
    Nicolas Meyer
    Céline Colacios
    Bruno Ségui
    Nature Communications, 8
  • [7] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [8] Impact of PD-L1 feedback modulation on the sensitivity of anti-PD-1/PD-L1
    Zhu, Jian
    Zhu, Rebecca L.
    CANCER RESEARCH, 2019, 79 (13)
  • [9] Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive nonsquamous NSCLC.
    Skoulidis, Ferdinandos
    Carter, Brett W.
    Zhang, Jianjun
    Wistuba, Ignacio Ivan
    Papadimitrakopoulou, Vassiliki
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
    Funaishi, Kunihiko
    Yamaguchi, Kakuhiro
    Tanahashi, Hiroki
    Kurose, Koji
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Oga, Toru
    Oka, Mikio
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
12345